Assenagon Asset Management S.A. Buys 409 Shares of Humana Inc. (NYSE:HUM)

Assenagon Asset Management S.A. raised its stake in Humana Inc. (NYSE:HUM) by 8.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,378 shares of the insurance provider’s stock after acquiring an additional 409 shares during the period. Assenagon Asset Management S.A.’s holdings in Humana were worth $1,423,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Dodge & Cox raised its stake in Humana by 106.7% in the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock valued at $2,587,345,000 after purchasing an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. increased its holdings in Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after buying an additional 1,751,857 shares during the period. Norges Bank acquired a new position in shares of Humana in the 4th quarter valued at approximately $416,202,000. Pzena Investment Management LLC lifted its holdings in shares of Humana by 44.0% during the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after acquiring an additional 1,103,132 shares during the period. Finally, Boston Partners lifted its holdings in shares of Humana by 435.8% during the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock worth $279,236,000 after acquiring an additional 893,637 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

NYSE HUM opened at $241.38 on Wednesday. The company has a market capitalization of $29.13 billion, a price-to-earnings ratio of 17.07, a PEG ratio of 1.78 and a beta of 0.43. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.71. Humana Inc. has a twelve month low of $212.45 and a twelve month high of $406.46. The stock has a fifty day simple moving average of $248.65 and a 200 day simple moving average of $261.84.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. The firm had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a return on equity of 14.47% and a net margin of 1.42%. The business’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $7.23 EPS. Sell-side analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a yield of 1.47%. Humana’s dividend payout ratio (DPR) is currently 25.04%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Truist Financial decreased their price objective on shares of Humana from $305.00 to $280.00 and set a “hold” rating on the stock in a research note on Tuesday. Robert W. Baird lifted their price target on Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, April 15th. Oppenheimer boosted their price target on Humana from $300.00 to $310.00 and gave the stock an “outperform” rating in a report on Thursday, May 1st. JPMorgan Chase & Co. reduced their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 target price on shares of Humana in a research note on Thursday, May 1st. Seventeen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Humana has an average rating of “Hold” and a consensus target price of $280.76.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.